Gastroenterology. 2009 Sep;137(3):856-64, 864.e1. doi: 10.1053/j.gastro.2009.06.006. Epub 2009 Jun 12.
PMID:19524577
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ.
Ann Oncol. 2021 Jun;32(6):746-756. doi: 10.1016/j.annonc.2021.03.005. Epub 2021 Mar 16.
PMID:33741442
Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial.
Thompson HM, Omer DM, Lin S, Kim JK, Yuval JB, Verheij FS, Qin LX, Gollub MJ, Wu AJ, Lee M, Patil S, Hezel AF, Marcet JE, Cataldo PA, Polite BN, Herzig DO, Liska D, Oommen S, Friel CM, Ternent CA, Coveler AL, Hunt SR, Garcia-Aguilar J; OPRA Consortium.
JAMA Netw Open. 2024 Jan 2;7(1):e2350903. doi: 10.1001/jamanetworkopen.2023.50903.
PMID:38194231
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK.
Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.
Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst AM, Chan YH, Aminkeng F, Bharwani LD, Huang Y, Mak A, Wong ASC.
Front Immunol. 2022 Jan 28;13:807050. doi: 10.3389/fimmu.2022.807050. eCollection 2022.
PMID:35154124
Metformin for the Prevention of Antipsychotic-Induced Weight Gain: Guideline Development and Consensus Validation.
Carolan A, Hynes-Ryan C, Agarwal SM, Bourke R, Cullen W, Gaughran F, Hahn MK, Krivoy A, Lally J, Leucht S, Lyne J, McCutcheon RA, Norton MJ, O'Connor K, Perry BI, Pillinger T, Shiers D, Siskind D, Thompson A, O'Shea D, Keating D, O'Donoghue B.
Schizophr Bull. 2024 Dec 9:sbae205. doi: 10.1093/schbul/sbae205. Online ahead of print.
PMID:39657713
Risk group-adapted adjuvant radiotherapy for WHO grade I and II skull base meningioma.
Park S, Cha YJ, Suh SH, Lee IJ, Lee KS, Hong CK, Kim JW.
J Cancer Res Clin Oncol. 2019 May;145(5):1351-1360. doi: 10.1007/s00432-019-02891-6. Epub 2019 Apr 5.
PMID:30953136
Observational management of Grade II or higher blunt traumatic thoracic aortic injury: 15 years of experience at a single suburban institution.
Ye JB, Lee JY, Lee JS, Kim SH, Choi H, Kim Y, Yoon SY, Sul YH, Choi JH.
Int J Crit Illn Inj Sci. 2022 Apr-Jun;12(2):101-105. doi: 10.4103/ijciis.ijciis_89_21. Epub 2022 Jun 24.
PMID:35845121
Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
Prognostic relevance of gemistocytic grade II astrocytoma: gemistocytic component and MR imaging features compared to non-gemistocytic grade II astrocytoma.
Heo YJ, Park JE, Kim HS, Lee JY, Nam SJ, Jung SC, Choi CG, Kim SJ.
Eur Radiol. 2017 Jul;27(7):3022-3032. doi: 10.1007/s00330-016-4649-z. Epub 2016 Nov 17.